Cambrian Bioworks secures $1.45 million in seed funding

New Delhi: Cambrian Bioworks has raised $1.45 million in seed funding to advance its cutting-edge solutions for the next-generation sequencing (NGS) and molecular diagnostics markets. The seed round was led by the Irani family office, which has a history of investing in private ventures globally, and saw additional support from Cambrian’s CEO and co-founder, Vaibhav Hegde.

Commenting on the investment, Hari Prasad of Kyra Ventures, representing the lead investor, expressed, “We’re very excited to back Cambrian Bioworks in their mission to elevate medical diagnostics in India. This team is building products for niches that solve fundamental problems in healthcare delivery.”

The funds will be crucial in accelerating the development of Cambrian’s automated molecular diagnostics platforms. The capital injection will also be used to bolster the company’s R&D efforts, expand its team, and support its expansion into international markets.

Cambrian Bioworks’ CEO, Vaibhav Hegde, emphasized, “Molecular diagnostics is crucial for precise diagnosis, disease subtyping, and therapy selection in cancer care. This funding marks a significant milestone in our journey.”

The announcement follows the recent launch of Cambrian’s nucleic acid extraction platform, Manta. This advanced automation technology provides high-quality DNA/RNA for genomics and PCR testing in hospitals and laboratories. Cambrian aims to leverage this momentum to make automated devices for liquid biopsy testing and targeted sequencing more widely accessible.

Founded by Vaibhav Hegde, Rohit Asil, and Raghav Sridhar, Cambrian Bioworks is focused on developing innovative automated molecular diagnostic platforms. The company’s products are designed for applications in oncology, genomics, rare disease testing, and antimicrobial resistance (AMR) detection.